Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 20/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20806966 | 1.00 | KRAS (0.66) | KRAS | |
| SCHEMBL22178432 | 0.95 | KRAS (0.67) | KRAS | |
| SCHEMBL20805595 | 0.88 | KRAS (0.67) | KRAS | |
| SCHEMBL22177712 | 0.87 | KRAS (0.66) | KRAS | |
| SCHEMBL24462648 | 0.80 | KRAS (0.69) | KRAS | |
| SCHEMBL24462680 | 0.80 | KRAS (0.63) | KRAS | |
| SCHEMBL20788879 | 0.80 | KRAS (1.00) | KRAS | |
| SCHEMBL20788880 | 0.80 | KRAS (1.00) | KRAS | |
| SCHEMBL20807081 | 0.80 | KRAS (0.61) | KRAS | |
| SCHEMBL24600169 | 0.79 | KRAS (0.48) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10640504-B2 | Inhibitors of KRAS G12C and methods of using the same | AMGEN INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190077801-A1 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | AMGEN INC. | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10640504-B2 | Inhibitors of KRAS G12C and methods of using the same | KRAS, NRAS, HRAS | KRAS 1/4885 |
| US-20190077801-A1 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | KRAS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.